PBAC's latest decision on Anakinra: Not recommended (2017). Considered for Amendment of PBS listing from Authority Required (STREAMLINED) to Authority Required for treatment of patients with moderate to severe cryopyrin associated periodic syndromes (CAPS).
PBAC outcome
Not recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2014
Submissions
3
2014 → 2017
Eligible population
Adult and paediatric patients with moderate to severe cryopyrin associated periodic syndromes (CAPS).
Therapy area
Rare disease
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Economic model
Not modelled
ICER note
Minor submission with no economic evaluation; no ICER calculated.
Risk sharing
Risk-sharing arrangement in place — A Risk Sharing Arrangement was established at the time of the November 2014 PBAC recommendation to manage any risk of leakage into rheumatoid arthritis and mild forms of CAPS.
Why PBAC said no
Reasons cited in the latest PSD: No clinical basis to change the level of authority; current restriction level considered appropriate; submission provided no evidence to support claim of use outside current restriction.
Submission history
Nov 2014: Recommended with restriction · Authority Required
Jul 2015: Recommended with restriction · Restricted